20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Recursion Pharmaceuticals Inc (RXRX) operates in the BIOTECHNOLOGY industry and is headquartered in Salt Lake City, United States with about 600 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, RXRX reported $75M in revenue and ($645M) in net income.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Interactive charts & full statements → Open the RXRX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $55M | $75M | $59M | $44M | $40M | $10M | $3M | $2M |
| Gross Profit | ($26M) | ($46M) | $14M | $1M | ($9M) | $10M | $3M | ($44M) |
| Gross Margin % | -46.7% | -62.0% | 23.1% | 2.9% | -21.7% | 100.0% | 100.0% | -2577.3% |
| Operating Income (EBIT) | ($544M) | ($648M) | ($479M) | ($350M) | ($246M) | ($183M) | ($85M) | ($62M) |
| Operating Margin % | -991.7% | -867.9% | -814.1% | -797.8% | -619.3% | -1827.8% | -2479.2% | -3649.4% |
| Net Income | ($519M) | ($645M) | ($464M) | ($328M) | ($239M) | ($178M) | ($87M) | ($63M) |
| Net Margin % | -945.9% | -863.4% | -788.0% | -747.7% | -603.4% | -1780.7% | -2549.2% | -3654.3% |
| EBITDA | ($444M) | ($559M) | ($427M) | ($308M) | ($234M) | ($174M) | ($82M) | ($58M) |
| Earnings Per Share (EPS) | $-1.04 | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 | $-0.38 |
| Shares Outstanding (M) | 532M | 447M | 274M | 208M | 176M | 170M | 166M | 166M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $8M | $6M | $36M | $5M | $19M | $15M | $5M | $26M |
| Gross Profit | ($4M) | ($6M) | $9M | ($24M) | ($1M) | ($7M) | ($8M) | $14M |
| Gross Margin % | -49.8% | -93.0% | 24.4% | -471.8% | -5.5% | -48.0% | -183.6% | 53.7% |
| Operating Income (EBIT) | ($135M) | ($129M) | ($108M) | ($172M) | ($176M) | ($191M) | ($184M) | ($98M) |
| Operating Margin % | -1759.7% | -1985.5% | -304.8% | -3327.6% | -922.5% | -1297.9% | -4073.8% | -377.1% |
| Net Income | ($131M) | ($118M) | ($108M) | ($162M) | ($172M) | ($202M) | ($179M) | ($96M) |
| Net Margin % | -1708.0% | -1815.6% | -304.2% | -3135.3% | -899.8% | -1373.3% | -3966.0% | -366.8% |
| EBITDA | ($113M) | ($102M) | ($89M) | ($141M) | ($148M) | ($183M) | ($165M) | ($88M) |
| Earnings Per Share (EPS) | $-0.25 | $-0.22 | $-0.21 | $-0.36 | $-0.41 | $-0.50 | $-0.53 | $-0.34 |
| Shares Outstanding (M) | 532M | 529M | 527M | 447M | 417M | 403M | 336M | 283M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($350M) | ($372M) | ($359M) | ($288M) | ($84M) | ($159M) | ($45M) | ($57M) |
| Capital Expenditures (CapEx) | $4M | $6M | $14M | $12M | $37M | $40M | $7M | $4M |
| Free Cash Flow (FCF) | ($354M) | ($378M) | ($373M) | ($300M) | ($121M) | ($198M) | ($52M) | ($61M) |
| FCF Margin % | -645.8% | -506.5% | -633.7% | -683.1% | -304.6% | -1984.1% | -1527.5% | -3562.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($106M) | ($81M) | ($46M) | ($117M) | ($76M) | ($132M) | ($115M) | ($59M) |
| Capital Expenditures (CapEx) | $2M | $0M | $1M | $0M | $3M | $2M | $2M | $5M |
| Free Cash Flow (FCF) | ($108M) | ($81M) | ($47M) | ($118M) | ($80M) | ($134M) | ($117M) | ($64M) |
| FCF Margin % | -1406.9% | -1258.3% | -133.1% | -2272.5% | -416.5% | -907.3% | -2595.4% | -244.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B | $1.5B | $1.4B | $654M | $701M | $610M | $299M | $101M |
| Cash & Cash Equivalents | $546M | $743M | $594M | $392M | $550M | $285M | $262M | $70M |
| Total Liabilities | $298M | $343M | $414M | $190M | $215M | $67M | $505M | $226M |
| Total Debt (Short + Long-Term) | $27M | $31M | $41M | $7M | $7M | $2M | $13M | $13M |
| Total Shareholders' Equity | $915M | $1.1B | $1.0B | $463M | $486M | $543M | ($206M) | ($124M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RXRX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms